Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Potent SARS inhibitors identified

April 3, 2006 | A version of this story appeared in Volume 84, Issue 14

Small-molecule agents that represent the most potent inhibitors yet known of the protease of severe acute respiratory syndrome virus have been identified. SARS, a contagious and potentially fatal respiratory condition caused by a coronavirus, was first reported in Asia several years ago and still cannot be effectively treated. Its protease plays an essential role in viral replication and is thus a promising target for anti-SARS therapeutics. Although a few inhibitors have been found, none are highly potent (that is, none have activities in the low nanomolar range), and no preclinical testing of the agents has been reported. Now a series of potent small-molecule inhibitors, like the 7.5-nM agent shown, have been identified by Po-Huang Liang of Academia Sinica, Taipei, Taiwan; Chi-Huey Wong of Scripps Research Institute; and coworkers (Chem. Biol. 2006, 13, 261). The benzotriazole esters act as suicide inhibitors by bonding irreversibly to a key site on the virus.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.